ଆଲଗ୍ଲୁକୋସିଡେଜ ଆଲଫା

<span title="International nonproprietary name (INN): <nowiki>Mr. Ibrahem/Alglucosidase alfa</nowiki>">Mr. Ibrahem/Alglucosidase alfa
Clinical data
Trade names	Myozyme, Lumizyme, others
AHFS/Drugs.com	Monograph
License data	<abbr class="country-name" title="<nowiki>European Union</nowiki>">EU EMA: by INN[permanent dead link]; <abbr class="country-name" title="<nowiki>United States</nowiki>">US DailyMed: Alglucosidase_alfa;
Routes of; ; administration	Intravenous
Drug class	Enzyme
Legal status
Legal status	<abbr class="country-name" title="<nowiki>Australia</nowiki>">AU: S4 (Prescription only) ; <abbr class="country-name" title="<nowiki>United States</nowiki>">US: ℞-only ;
Identifiers
	IUPAC name Human glucosidase, prepro-α-[199-arginine,223-histidine] ;
Chemical and physical data
Formula	C4758H7262N1274O1369S35
Molar mass	105338 g·mol−1
	(what is this?) (verify)

ଆଲଗ୍ଲୁକୋସିଡେଜ ଆଲଫା, ବିକ୍ରୟ ନାମ ମାୟୋଜାଇମ, ଏକ ଔଷଧ ଯାହା ପମ୍ପେ ରୋଗ (ଗ୍ଲାଇକୋଜେନ୍ ଷ୍ଟୋରେଜ୍ ରୋଗ ପ୍ରକାର ୨)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହାର କରାଯାଏ । ^[୫] ଏହା ଏକ ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକ୍ସନ ଦେଇ ଦିଆଯାଏ । ^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା, ଜ୍ୱର, ମୁଣ୍ଡବିନ୍ଧା, ଝାଳ, ଅଇ, ଥକାପଣ ଏବଂ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ହୋଇପାରେ । ^[୧] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆନାଫାଇଲକ୍ସିସ୍ ହୋଇପାରେ । ^[୧] ଏହା ଏକ ଏନଜାଇମ୍ ଯାହା ନିଖୋଜ ଆଲଫା-ଗ୍ଲୁକୋସିଡେଜକୁ ପୁନଃ‌ସ୍ଥାପନ କରିଥାଏ । ^[୩]

୨୦୦୬ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଆଲଗ୍ଲୁକୋସିଡେଜ ଆଲଫା ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୫]^[୩] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ £୩୬୦ ଅଟେ । ^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ମୂଲ୍ୟ ୯୦୦ ଡଲାର ଅଟେ । ^[୭]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Lumizyme- alglucosidase alfa injection, powder, for solution". DailyMed. 22 February 2020. Archived from the original on 25 March 2021. Retrieved 14 August 2020.
↑ "FDA Approves First Treatment for Pompe Disease".
↑ ^୩.୦ ^୩.୧ ^୩.୨ "Myozyme".
↑ ^୪.୦ ^୪.୧ ^୪.୨ American Medical Association (USAN).
↑ ^୫.୦ ^୫.୧ "Alglucosidase Alfa Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 November 2019. Retrieved 13 January 2022.
↑ ^୬.୦ ^୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1117. ISBN 978-0857114105.
↑ "Lumizyme Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 13 January 2022.

[PI2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ "Lumizyme- alglucosidase alfa injection, powder, for solution". DailyMed. 22 February 2020. Archived from the original on 25 March 2021. Retrieved 14 August 2020.

[FDA2006-2] "FDA Approves First Treatment for Pompe Disease".

[EPAR2022-3] ୩.୦ ^୩.୧ ^୩.୨ "Myozyme".

[USAN-4] ୪.୦ ^୪.୧ ^୪.୨ American Medical Association (USAN).

[AHFS2022-5] ୫.୦ ^୫.୧ "Alglucosidase Alfa Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 November 2019. Retrieved 13 January 2022.

[BNF81-6] ୬.୦ ^୬.୧ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1117. ISBN 978-0857114105.

[7] "Lumizyme Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 13 January 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]